Quantitative data describing the impact of the flavonol rutin on in-vivo blood-glucose and fluid-intake profiles, and survival of human-amylin transgenic mice.
Quantitative data describing the impact of the flavonol rutin on in-vivo blood-glucose and fluid-intake profiles, and survival of human-amylin transgenic mice.
复制标题
DOI：
10.1016/j.dib.2016.11.077
复制
发表时间：
2017-02
期刊：
影响因子：
1.2
通讯作者：
Cooper, Garth J S
中科院分区：
文献类型：
--
作者：
Aitken, Jacqueline F;Loomes, Kerry M;Riba-Garcia, Isabel;Unwin, Richard D;Prijic, Gordana;Phillips, Ashley S;Phillips, Anthony R J;Wu, Donghai;Poppitt, Sally D;Ding, Ke;Barran, Perdita E;Dowsey, Andrew W;Cooper, Garth J S
本研究提供的数据描述了口服芦丁的糖尿病半合子人胰黑素（hA）转基因小鼠的血糖和液体摄入量的时间过程，以及饮水的对照小鼠。我们采用“参数变化点回归分析”来调查对照组和芦丁治疗组之间的时间过程差异，以提取每只动物的基线血糖和液体摄入量水平，血糖（糖尿病发病）和液体摄入量（多饮发病）加速偏离基线的变化点时间，以及这种加速的速度。这里应用的参数变点回归方法可以比标准诊断标准更准确地确定糖尿病发病的确切时间。这些数据与题为“鲁丁抑制体外人amylin/hIAPP错误折叠和低聚物形成，并改善糖尿病及其对人amylin/hIAPP转基因小鼠的影响”的文章有关（J.F. Aitken， K.M. Loomes， I. Riba-Garcia， R.D. Unwin， G. Prijic， A.S. Phillips， A.R.J. Phillips， D. Wu， S.D. Poppitt， K. Ding， P.E. Barran， A.W. Dowsey， G.J.S. Cooper. 2016）。
Here we provide data describing the time-course of blood-glucose and fluid-intake profiles of diabetic hemizygous human-amylin (hA) transgenic mice orally treated with rutin, and matched control mice treated with water. We employed “parametric change-point regression analysis” for investigation of differences in time-course profiles between the control and rutin-treatment groups to extract, for each animal, baseline levels of blood glucose and fluid-intake, the change-point time at which blood glucose (diabetes-onset) and fluid-intake (polydipsia-onset) accelerated away from baseline, and the rate of this acceleration. The parametric change-point regression approach applied here allowed a much more accurate determination of the exact time of onset of diabetes than do the standard diagnostic criteria. These data are related to the article entitled “Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice” (J.F. Aitken, K.M. Loomes, I. Riba-Garcia, R.D. Unwin, G. Prijic, A.S. Phillips, A.R.J. Phillips, D. Wu, S.D. Poppitt, K. Ding, P.E. Barran, A.W. Dowsey, G.J.S. Cooper. 2016).